• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden.瑞典一项两年一次的随机前列腺癌筛查项目中前列腺特异性抗原水平个体内变异的评估。
Prostate. 2005 Nov 1;65(3):216-21. doi: 10.1002/pros.20286.
2
Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.在对前列腺癌进行评估的男性的一系列血液采集样本中,前列腺特异性抗原和其他激肽释放酶标志物的个体内短期变异性。
BJU Int. 2011 Jun;107(11):1769-74. doi: 10.1111/j.1464-410X.2010.09761.x. Epub 2010 Oct 18.
3
Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.在血清中检测人腺激肽释放酶2以及游离和总前列腺特异性抗原用于前列腺癌的半年一次筛查。
J Urol. 2003 Oct;170(4 Pt 1):1169-74. doi: 10.1097/01.ju.0000086640.19892.0b.
4
Percent free PSA as an additional measure in a prostate cancer screen.游离前列腺特异抗原百分比作为前列腺癌筛查的一项附加指标。
Clin Lab Sci. 2001 Spring;14(2):102-7.
5
Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.人腺激肽释放酶2及游离和总前列腺特异性抗原在前列腺特异性抗原水平为3.0 ng/mL或更高的男性人群血清中的临床价值。
Urology. 2000 May;55(5):694-9. doi: 10.1016/s0090-4295(99)00585-3.
6
Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden.在瑞典通过检测血清游离和总前列腺特异性抗原进行基于人群的前列腺癌筛查。
BJU Int. 2003 Dec;92 Suppl 2:39-43. doi: 10.1111/j.1465-5101.2003.04396.x.
7
Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.前列腺癌的长期预测:在一个大型、具有代表性且未接受筛查的人群中,前列腺特异性抗原(PSA)速度具有预测性,但在癌症诊断前15年或更久之前,它并不能提高单次PSA测量的预测准确性。
J Clin Oncol. 2008 Feb 20;26(6):835-41. doi: 10.1200/JCO.2007.13.1490.
8
Low percentage of free prostate-specific antigen (PSA) is a strong predictor of later detection of prostate cancer among Japanese men with serum levels of total PSA of 4.0 ng/mL or less.在总前列腺特异性抗原(PSA)血清水平为4.0 ng/mL或更低的日本男性中,游离前列腺特异性抗原(PSA)比例较低是前列腺癌后期检测的有力预测指标。
Urology. 2014 Nov;84(5):1163-7. doi: 10.1016/j.urology.2014.04.055. Epub 2014 Oct 24.
9
Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.血清中人腺激肽释放酶2水平用于在总前列腺特异抗原水平低于10 ng/ml时鉴别病理局限于器官的前列腺癌与局部进展性前列腺癌。
Prostate. 2001 Oct 1;49(2):101-9. doi: 10.1002/pros.1123.
10
Age-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients.约旦患者前列腺特异性抗原(PSA)的年龄特异性参考范围。
Prostate Cancer Prostatic Dis. 2003;6(3):256-60. doi: 10.1038/sj.pcan.4500656.

引用本文的文献

1
Serum levels of prostate specific antigen, free PSA, [-2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy.良性前列腺增生药物治疗患者的血清前列腺特异性抗原、游离前列腺特异性抗原、[-2]前列腺特异性抗原前体、游离前列腺特异性抗原/总前列腺特异性抗原比值、前列腺健康指数及游离前列腺特异性抗原的糖基化模式
Prostate. 2025 Jan;85(1):65-72. doi: 10.1002/pros.24801. Epub 2024 Sep 27.
2
Psychological impact of serial prostate-specific antigen tests in Japanese men waiting for prostate biopsy.等待前列腺活检的日本男性进行系列前列腺特异性抗原检测的心理影响
Int J Clin Oncol. 2017 Feb;22(1):174-180. doi: 10.1007/s10147-016-1038-1. Epub 2016 Sep 8.
3
A Review on the Clinical Utility of PSA in Cancer Prostate.前列腺特异性抗原(PSA)在前列腺癌中的临床应用综述
Indian J Surg Oncol. 2012 Jun;3(2):120-9. doi: 10.1007/s13193-012-0142-6. Epub 2012 Mar 3.
4
Tumor markers in prostate cancer I: blood-based markers.前列腺癌的肿瘤标志物 I:基于血液的标志物。
Acta Oncol. 2011 Jun;50 Suppl 1(Suppl 1):61-75. doi: 10.3109/0284186X.2010.542174.
5
Screening for prostate cancer: an update.前列腺癌筛查:最新进展
Can J Urol. 2008 Dec;15(6):4363-74.

本文引用的文献

1
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.前列腺特异性抗原水平≤4.0纳克/毫升的男性中前列腺癌的患病率。
N Engl J Med. 2004 May 27;350(22):2239-46. doi: 10.1056/NEJMoa031918.
2
Detection of prostate cancer in men with prostate-specific antigen levels of 2.0 to 4.0 ng/mL equivalent to that in men with 4.1 to 10.0 ng/mL in a Japanese population.在日本人群中,前列腺特异性抗原水平为2.0至4.0 ng/mL的男性中前列腺癌的检测情况与前列腺特异性抗原水平为4.1至10.0 ng/mL的男性相当。
Urology. 2004 Apr;63(4):727-31. doi: 10.1016/j.urology.2003.11.025.
3
Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.一项基于人群的随机研究结果,该研究采用血清前列腺特异性抗原检测进行两年一次的筛查以检测前列腺癌。
Cancer. 2004 Apr 1;100(7):1397-405. doi: 10.1002/cncr.20126.
4
Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation.肾移植后游离前列腺特异性抗原和人激肽释放酶2通过肾小球滤过快速清除。
J Urol. 2004 Apr;171(4):1432-5. doi: 10.1097/01.ju.0000118580.19344.68.
5
Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).低前列腺特异性抗原水平下的前列腺特异性抗原变化率作为前列腺癌筛查工具:欧洲前列腺癌筛查随机对照研究(鹿特丹)第二轮筛查结果
Urology. 2004 Feb;63(2):309-13; discussion 313-5. doi: 10.1016/j.urology.2003.09.083.
6
Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations.血清前列腺特异性抗原水平的变化:逐年波动情况评估
JAMA. 2003 May 28;289(20):2695-700. doi: 10.1001/jama.289.20.2695.
7
Use of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer.
Prostate Cancer Prostatic Dis. 2003;6(1):39-44. doi: 10.1038/sj.pcan.4500614.
8
Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment.接受血液透析或腹膜透析治疗的男性,其游离前列腺特异性抗原百分比会升高。
Nephrol Dial Transplant. 2003 Mar;18(3):598-603. doi: 10.1093/ndt/18.3.598.
9
Day to day changes in free and total PSA: significance of biological variation.
Prostate Cancer Prostatic Dis. 1997 Dec;1(2):90-96. doi: 10.1038/sj.pcan.4500212.
10
Intraindividual variation of PSA, free PSA and complexed PSA in a cohort of patients with prostate cancer managed with watchful observation.
Clin Biochem. 2002 Sep;35(6):471-5. doi: 10.1016/s0009-9120(02)00345-4.

瑞典一项两年一次的随机前列腺癌筛查项目中前列腺特异性抗原水平个体内变异的评估。

Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden.

作者信息

Bruun Laila, Becker Charlotte, Hugosson Jonas, Lilja Hans, Christensson Anders

机构信息

Department of Nephrology and Transplantation, Lund University, University Hospital (UMAS), Malmö, Sweden.

出版信息

Prostate. 2005 Nov 1;65(3):216-21. doi: 10.1002/pros.20286.

DOI:10.1002/pros.20286
PMID:15948137
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1951509/
Abstract

BACKGROUND

The degree of variability in prostate-specific antigen (PSA) measurements is important for interpreting test results in screening programs, and particularly for interpreting the significance of changes between repeated tests. This study aimed to determine the long-term intra-individual variation for PSA in healthy men.

METHODS

A randomly selected cohort of men in a biennial prostate cancer screening program (ERSPC) conducted in Sweden from 1995-1996 to 2001-2002. We studied men who had total PSA (tPSA) levels < 2.0 ng/ml in 2001-2002. This included 791 men with tPSA < or = 0.61 ng/ml (group A), 1,542 men with tPSA < or = 0.99 ng/ml (group B), and 1,029 men with tPSA 1.00-1.99 ng/ml (group C). The intra-individual variability of free PSA (fPSA) and tPSA was assessed by calculating coefficients of variation (CV) for each individual's PSA measurements from the first and second round of screening (1995-1996 and 1997-1998).

RESULTS

Intra-individual CV (geometric means) for tPSA were 13.7%, 12.7%, and 11.5% in groups A, B, and C, respectively. Corresponding CVs for fPSA were significantly lower, ranging from 12.1% to 10.4%. The estimated biological variation of tPSA and fPSA in groups A to C were 12.5%, 11.4%, 10.0% and 9.7%, 7.8%, 7.5%, respectively.

CONCLUSIONS

In healthy men with PSA levels less than 2 ng/ml, the natural long-term variability for tPSA was less than 14%, and with 95% probability, a change in tPSA greater than 30% indicates a change beyond normal random variation.

摘要

背景

前列腺特异性抗原(PSA)测量值的变异程度对于解读筛查项目中的检测结果很重要,尤其对于解读重复检测之间变化的意义。本研究旨在确定健康男性PSA的长期个体内变异。

方法

在瑞典于1995 - 1996年至2001 - 2002年开展的一项两年一次的前列腺癌筛查项目(ERSPC)中随机选取一组男性。我们研究了在2001 - 2002年总PSA(tPSA)水平<2.0 ng/ml的男性。这包括791名tPSA≤0.61 ng/ml的男性(A组)、1542名tPSA≤0.99 ng/ml的男性(B组)以及1029名tPSA为1.00 - 1.99 ng/ml的男性(C组)。通过计算每位男性在第一轮和第二轮筛查(1995 - 1996年和1997 - 1998年)中PSA测量值的变异系数(CV)来评估游离PSA(fPSA)和tPSA的个体内变异性。

结果

A组、B组和C组中tPSA的个体内CV(几何均值)分别为13.7%、12.7%和11.5%。fPSA的相应CV显著更低,范围为12.1%至10.4%。A组至C组中tPSA和fPSA的估计生物学变异分别为12.5%、11.4%、10.0%和9.7%、7.8%、7.5%。

结论

在PSA水平低于2 ng/ml的健康男性中,tPSA的自然长期变异小于14%,并且有95%的概率,tPSA变化大于30%表明变化超出正常随机变异范围。